{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:22Z","timestamp":1786982722882,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s40120-023-00562-w","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T05:02:03Z","timestamp":1699592523000},"page":"85-105","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct05127486","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Todd J.","family":"Schwedt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4507-6056","authenticated-orcid":false,"given":"Tina M.","family":"Myers Oakes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert B.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitendra","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Pearlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane R.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oralee J.","family":"Varnado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cobas Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Goadsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,10]]},"reference":[{"key":"562_CR1","doi-asserted-by":"crossref","unstructured":"Diener HC, Tfelt-Hansen P, Dahlof C, et al. Topiramate in migraine prophylaxis\u2014results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2004;251:943\u201350.","DOI":"10.1007\/s00415-004-0464-6"},{"key":"562_CR2","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1177\/03331024211047454","volume":"42","author":"D Chowdhury","year":"2022","unstructured":"Chowdhury D, Bansal L, Duggal A, et al. TOP-PRO study: a randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine. Cephalalgia. 2022;42:396\u2013408.","journal-title":"Cephalalgia"},{"key":"562_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/03331024211053571","volume":"42","author":"U Reuter","year":"2022","unstructured":"Reuter U, Ehrlich M, Gendolla A, et al. Erenumab versus topiramate for the prevention of migraine\u2014a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia. 2022;42:108\u201318.","journal-title":"Cephalalgia"},{"key":"562_CR4","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1056\/NEJMoa030505","volume":"350","author":"J Olesen","year":"2004","unstructured":"Olesen J, Diener H-C, Husstedt IW, BIBN 4096 BS Clinical Proof of Concept Study Group, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350:1104\u201310.","journal-title":"N Engl J Med"},{"issue":"9656","key":"562_CR5","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(08)61626-8","volume":"372","author":"TW Ho","year":"2008","unstructured":"Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008;372(9656):2115\u201323.","journal-title":"Lancet"},{"key":"562_CR6","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/0333102410388435","volume":"31","author":"HC Diener","year":"2011","unstructured":"Diener HC, Barbanti P, Dahl\u00f6f C, Reuter U, Habeck J, Podhorna J. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011;31:573\u201384.","journal-title":"Cephalalgia"},{"key":"562_CR7","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1177\/0333102411398399","volume":"31","author":"DJ Hewitt","year":"2011","unstructured":"Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011;31:712\u201322.","journal-title":"Cephalalgia"},{"key":"562_CR8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/0333102413500727","volume":"34","author":"R Marcus","year":"2014","unstructured":"Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34:114\u201325.","journal-title":"Cephalalgia"},{"key":"562_CR9","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1177\/0333102416653233","volume":"36","author":"T Voss","year":"2016","unstructured":"Voss T, Lipton RB, Dodick DW, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016;36:887\u201398.","journal-title":"Cephalalgia"},{"issue":"11","key":"562_CR10","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1212\/WNL.0000000000000771","volume":"83","author":"TW Ho","year":"2014","unstructured":"Ho TW, Connor KM, Zhang Y, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology. 2014;83(11):958\u201366.","journal-title":"Neurology"},{"key":"562_CR11","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1007\/s00415-023-11706-1","volume":"270","author":"F Puledda","year":"2023","unstructured":"Puledda F, Silva EM, Suwanlaong K, Goadsby PJ. Migraine: from pathophysiology to treatment. J Neurol. 2023;270:3654\u201366.","journal-title":"J Neurol"},{"key":"562_CR12","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S1474-4422(14)70128-0","volume":"13","author":"DW Dodick","year":"2014","unstructured":"Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2014;13:885\u201392.","journal-title":"Lancet Neurol"},{"key":"562_CR13","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91:e2211\u201321.","journal-title":"Neurology"},{"key":"562_CR14","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38:1442\u201354.","journal-title":"Cephalalgia"},{"key":"562_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1001\/jamaneurol.2017.3859","volume":"75","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Oakes TM, Zhang Q, et al. Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol. 2018;75:187\u201393 (Erratum in: JAMA Neurol. 2018; 75:260).","journal-title":"JAMA Neurol"},{"key":"562_CR16","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang QI, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75:1080\u20138.","journal-title":"JAMA Neurol"},{"key":"562_CR17","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","volume":"19","author":"WM Mulleners","year":"2020","unstructured":"Mulleners WM, Kim BK, Lainez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19:814\u201325.","journal-title":"Lancet Neurol"},{"key":"562_CR18","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.joca.2014.01.009","volume":"22","author":"RJ Benschop","year":"2014","unstructured":"Benschop RJ, Collins EC, Darling RJ, et al. Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain. Osteoarthritis Cartil. 2014;22:578\u201385 (Erratum in: Osteoarthritis Cartilage. 2014; 22:1951. Nisenbaum ES [added]).","journal-title":"Osteoarthritis Cartil"},{"issue":"10268","key":"562_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51\u201360.","journal-title":"Lancet"},{"key":"562_CR20","doi-asserted-by":"crossref","unstructured":"Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394:737\u201345.","DOI":"10.1016\/S0140-6736(19)31606-X"},{"key":"562_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381:142\u20139.","journal-title":"N Engl J Med"},{"key":"562_CR22","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd ed. Cephalalgia. 2018; 38:1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"562_CR23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1046\/j.1526-4610.1998.3804295.x","volume":"38","author":"P Jhingran","year":"1998","unstructured":"Jhingran P, Osterhaus JT, Miller DW, et al. Development and validation of the Migraine-Specific Quality of Life Questionnaire. Headache. 1998;38:295\u2013302.","journal-title":"Headache"},{"key":"562_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0304-3959(00)00305-5","volume":"88","author":"WF Stewart","year":"2000","unstructured":"Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain. 2000;88:41\u201352.","journal-title":"Pain"},{"key":"562_CR25","first-page":"217","volume-title":"ECDEU assessment manual for psychopharmacology, revised 1976","author":"W Guy","year":"1976","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology, revised 1976. Rockville: National Institute of Mental Health, Psychopharmacology Research Branch; 1976. p. 217\u201322."},{"key":"562_CR26","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2307\/2533558","volume":"53","author":"MG Kenward","year":"1997","unstructured":"Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics. 1997;53:983\u201397.","journal-title":"Biometrics"},{"key":"562_CR27","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/sim.3495","volume":"28","author":"F Bretz","year":"2009","unstructured":"Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures. Stat Medicine. 2009;28:586\u2013604.","journal-title":"Stat Medicine"},{"key":"562_CR28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1198\/sbr.2010.09014","volume":"3","author":"BA Millen","year":"2011","unstructured":"Millen BA, Dmitrienko A. Chain procedures: a class of flexible closed testing procedures with clinical trial applications. Stat Biopharm Res. 2011;3:14\u201330.","journal-title":"Stat Biopharm Res"},{"key":"562_CR29","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/sim.5537","volume":"32","author":"G Kordzakhia","year":"2013","unstructured":"Kordzakhia G, Dmitrienko A. Superchain procedures in clinical trials with multiple objectives. Stat Medicine. 2013;32:486\u2013508.","journal-title":"Stat Medicine"},{"key":"562_CR30","first-page":"735","volume":"11","author":"HC Diener","year":"2010","unstructured":"Diener HC. Placebo effects in treating migraine and other headaches. Curr Opin Investig Drugs. 2010;11:735\u20139.","journal-title":"Curr Opin Investig Drugs"},{"key":"562_CR31","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1177\/0333102419835459","volume":"39","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Paemeleire K, Broessner G, et al. Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2019;39:817\u201329.","journal-title":"Cephalalgia"},{"key":"562_CR32","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1177\/0333102418788347","volume":"10","author":"M Ashina","year":"2018","unstructured":"Ashina M, Tepper S, Brandes JL, et al. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2018;10:1611\u201321.","journal-title":"Cephalalgia"},{"key":"562_CR33","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstrom Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377:2123\u201332.","journal-title":"N Engl J Med"},{"key":"562_CR34","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319:1999\u20132008.","journal-title":"JAMA"},{"key":"562_CR35","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40:241\u201354.","journal-title":"Cephalalgia"},{"key":"562_CR36","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1474-4422(20)30234-9","volume":"19","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Dodick DW, Ailani J, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b\/3 trial. Lancet Neurol. 2020;19:727\u201337.","journal-title":"Lancet Neurol"},{"key":"562_CR37","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMoa2035908","volume":"385","author":"J Ailani","year":"2021","unstructured":"Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385:695\u2013706.","journal-title":"N Engl J Med"},{"key":"562_CR38","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s10194-018-0951-2","volume":"19","author":"S F\u00f6rderreuther","year":"2018","unstructured":"F\u00f6rderreuther S, Zhang Q, Stauffer VL, Aurora SK, L\u00e1inez MJA. Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. J Headache Pain. 2018;19:121.","journal-title":"J Headache Pain"},{"key":"562_CR39","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s10194-019-1024-x","volume":"20","author":"SD Silberstein","year":"2019","unstructured":"Silberstein SD, Stauffer VL, Day KA, Lipsius S, Wilson MC. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2). J Headache Pain. 2019;20:75 (Erratum in: J Headache Pain. 2019; 20:118).","journal-title":"J Headache Pain"},{"key":"562_CR40","unstructured":"Eli Lilly and Company. Emgality [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021. https:\/\/pi.lilly.com\/us\/emgality-uspi.pdf. Accessed 31 July 2023."},{"key":"562_CR41","unstructured":"Biohaven Pharmaceuticals, Inc. Nurtec [package insert]. New Haven, CT: Biohaven Pharmaceuticals, Inc.; 2023. https:\/\/www.pfizermedicalinformation.com\/en-us\/nurtec-odt. Accessed 31 July 2023."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00562-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-023-00562-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-023-00562-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T09:11:35Z","timestamp":1705137095000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-023-00562-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["562"],"URL":"https:\/\/doi.org\/10.1007\/s40120-023-00562-w","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,10]]},"assertion":[{"value":"6 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Todd Schwedt has received compensation for <i>consulting<\/i> for Abbvie, Allergan, Axsome, Collegium, Eli Lilly, Linpharma, Lundbeck, Satsuma, and Theranica; <i>research funding<\/i> from Amgen, Mayo Clinic, National Institutes of Health, Patient Centered Outcomes Research Institute, SPARK Neuro, and the United States Department of Defense; <i>stock options<\/i> in Aural Analytics and Nocira; and is on the <i>board of directors<\/i> for the American Headache Society and the American Migraine Foundation. Peter Goadsby reports, over the last 36 months, a <i>grant<\/i> from Celgene; <i>personal fees<\/i> from Aeon Biopharma, Abbvie, Amgen, CoolTech LLC, Dr Reddys, Eli Lilly and Company, Epalex, Lundbeck, Novartis, Pfizer, Praxis, Sanofi, Satsuma, Shiratronics, Teva Pharmaceuticals, and Tremeau; <i>personal fees for advice<\/i> through Gerson Lehrman Group, Guidepoint, SAI Med Partners, and Vector Metric; <i>fees for educational materials<\/i> from CME Outfitters; <i>publishing royalties or fees<\/i> from Massachusetts Medical Society, Oxford University Press, UptoDate, and Wolters Kluwer; and a <i>patent<\/i> for magnetic stimulation for headache (no. WO2016090333 A1) assigned to eNeura without fee. James Martinez, Michael Cobas Meyer, Tina Myers Oakes, Hitendra Pandey, Eric Pearlman, Diane Richardson, Bert Vargas, and Oralee Varnado are employees of Eli Lilly and Company, Indianapolis, IN, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by all institutions and the Advara, Inc. Institutional Review Board (Columbia, MD) utilized by all investigative sites that participated in the study (Table S2 in the electronic supplementary material). The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. All participants provided informed consent to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}